EPS for Seattle Genetics, Inc. (SGEN) Expected At $-0.42

October 13, 2017 - By Migdalia James

 EPS for Seattle Genetics, Inc. (SGEN) Expected At $ 0.42
Investors sentiment decreased to 1.3 in Q2 2017. Its down 0.20, from 1.5 in 2017Q1. It dived, as 30 investors sold Seattle Genetics, Inc. shares while 75 reduced holdings. 48 funds opened positions while 89 raised stakes. 137.48 million shares or 0.82% less from 138.62 million shares in 2017Q1 were reported.
Spark Invest Mngmt Llc holds 139,100 shares or 0.44% of its portfolio. Tributary Cap Management Ltd Limited Liability Company holds 0.09% or 20,200 shares in its portfolio. Pictet Asset Mgmt invested 0.14% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Quantitative Systematic Strategies Ltd Liability Corp invested 0.08% in Seattle Genetics, Inc. (NASDAQ:SGEN). Price T Rowe Assoc Inc Md reported 3.85 million shares. Kbc Group Nv owns 16,558 shares. Capital, California-based fund reported 2.72 million shares. 75,284 are held by Proshare Advisors Ltd Co. Raymond James Associates accumulated 8,191 shares. Creative Planning has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Quantbot Tech Limited Partnership owns 1,226 shares for 0.01% of their portfolio. Natl Planning Corporation invested 0.44% in Seattle Genetics, Inc. (NASDAQ:SGEN). Blair William & Co Il reported 668,546 shares or 0.26% of all its holdings. 22,300 were accumulated by Nationwide Fund. Employees Retirement Association Of Colorado accumulated 20,370 shares or 0.01% of the stock.

Since May 5, 2017, it had 0 buys, and 3 sales for $2.20 million activity. 14,462 shares were sold by SIEGALL CLAY B, worth $892,897. HIMES VAUGHN B also sold $625,922 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Wednesday, May 31.

Wall Street await Seattle Genetics, Inc. (NASDAQ:SGEN) to release earnings on October, 26. Analysts forecast earnings per share of $-0.42, down exactly $0.19 or 82.61 % from 2014’s $-0.23 EPS. After posting $-0.39 EPS for the previous quarter, Seattle Genetics, Inc.’s analysts now forecast 7.69 % negative EPS growth. The stock increased 0.49% or $0.3 during the last trading session, reaching $61.77. About 1.99M shares traded or 82.57% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since October 13, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 16 analysts covering Seattle Genetics (NASDAQ:SGEN), 6 have Buy rating, 1 Sell and 9 Hold. Therefore 38% are positive. Seattle Genetics had 45 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given on Friday, September 15 by Needham. On Friday, February 10 the stock rating was downgraded by Bank of America to “Underperform”. Cantor Fitzgerald maintained the shares of SGEN in report on Monday, June 26 with “Hold” rating. Barclays Capital downgraded the stock to “Equal-Weight” rating in Tuesday, November 29 report. The company was downgraded on Wednesday, July 27 by Cantor Fitzgerald. The stock has “Buy” rating by Jefferies on Monday, June 12. As per Monday, June 26, the company rating was maintained by Oppenheimer. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Outperform” rating by Credit Suisse on Thursday, January 21. H.C. Wainwright maintained the shares of SGEN in report on Monday, June 19 with “Buy” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Overweight” rating by Morgan Stanley on Wednesday, September 7.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $8.83 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Nasdaq.com which released: “Seattle Genetics Inks Clinical Collaborations for Cancer Drug” on October 12, 2017, also Nasdaq.com with their article: “Seattle Genetics’ Adcetris Gets Breakthrough Therapy Status” published on October 03, 2017, Zacks.com published: “Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher October 03, 2017” on October 03, 2017. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Streetinsider.com and their article: “Seattle Genetics (SGEN) & Astellas Commences Pivotal Trial of Enfortumab Vedotin” published on October 10, 2017 as well as Seekingalpha.com‘s news article titled: “Seattle Genetics: Good Time To Buy Based On Adcetris Label Expansion” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.